Open help menu
Live Webinar
GXC 2025 Online Virtual Conference - Mental Health Without Borders

The New Frontier of GLP-1Ra Medications in Addiction Treatment: What we know, what we don’t and what we’re doing.

Steven Klein, MD, PhD, FAAP 🇺🇸
|

Pricing

Information

Date & Time

Description

GLP-1 receptor agonists have emerged as one of the most promising developments in addiction medicine, with early evidence suggesting meaningful effects on craving, reward circuitry, impulse control, and relapse vulnerability. While traditionally used for diabetes and obesity, these medications are now being explored for their impact on homeostatic and hedonic pathways—offering a potential new class of neurometabolic interventions in substance use treatment. This session will explore what we currently know from neuroscience and clinical trials, what remains uncertain or misunderstood, and how programs like Caron are thoughtfully and ethically integrating GLP-1 therapy into real-world addiction treatment, research development, and brain-based outcomes tracking.

Learning Objectives

Participants will be able to:

  • Understand the Neurobiology of Addiction and Reward Pathways

  • Explore the Mechanisms of GLP-1R Agonists in the Brain

  • Evaluate the Evidence for GLP-1R Agonists in Treating Addiction

  • Identify Clinical Applications and Future Directions

Educational Goal

This presentation will enhance clinicians’ understanding of how GLP-1 receptor agonists influence craving, reward circuitry, and relapse vulnerability, allowing them to integrate emerging neuroscience into more informed and sophisticated addiction treatment planning. By expanding knowledge of neurometabolic interventions, clinicians will strengthen their ability to evaluate novel pharmacological approaches and apply them ethically and effectively in future practice.

Target Audience

  • Addiction Professional
  • Counselor
  • Marriage & Family Therapist
  • Nurse
  • Physician
  • Psychologist
  • Social Worker

Presenters

Steven Klein, MD, PhD, FAAP 🇺🇸
Dr. Steven Klein is a physician with board certifications in Pediatrics and Medical Genetics and is board eligible in Addiction Medicine. He brings a multidisciplinary and neurobiologically informed perspective to the treatment of substance use disorders at Caron Treatment Centers. As the Medical Provider for the Relapse Men’s Unit, he specializes in managing high-acuity, treatment-resistant cases using an integrated medical model that blends medication-assisted treatment, withdrawal management, metabolic therapies, and psychiatric care. Dr. Klein also provides medical oversight for young adults within Caron’s treatment continuum, ensuring developmentally attuned, medically comprehensive care across all levels of recovery. His work is rooted in data-driven innovation, with a focus on the clinical integration of GLP-1 receptor agonist therapies and the application of AI-enabled tools to enhance assessment, documentation, and treatment delivery in residential settings. His overarching mission is to advance addiction medicine by building clinically rigorous, research-informed, and human-centered care models that improve long-term outcomes and reduce relapse rates.

Financially Sponsored By

  • GXC Events - The Global Exchange Conference